KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBIT Margin: 2009-2025

Historic EBIT Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -102.21%.

  • Ionis Pharmaceuticals' EBIT Margin rose 888.00% to -102.21% in Q3 2025 from the same period last year, while for Sep 2025 it was -35.07%, marking a year-over-year increase of 1105.00%. This contributed to the annual value of -67.37% for FY2024, which is 2246.00% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' EBIT Margin stood at -102.21%, which was down 303.23% from 50.29% recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' EBIT Margin ranged from a high of 50.29% in Q2 2025 and a low of -136.95% during Q4 2022.
  • In the last 3 years, Ionis Pharmaceuticals' EBIT Margin had a median value of -87.45% in 2023 and averaged -64.96%.
  • Per our database at Business Quant, Ionis Pharmaceuticals' EBIT Margin surged by 34,008bps in 2021 and then crashed by 18,709bps in 2022.
  • Ionis Pharmaceuticals' EBIT Margin (Quarterly) stood at 50.14% in 2021, then plummeted by 18,709bps to -136.95% in 2022, then skyrocketed by 13,507bps to -1.89% in 2023, then slumped by 4,702bps to -48.91% in 2024, then spiked by 888bps to -102.21% in 2025.
  • Its last three reported values are -102.21% in Q3 2025, 50.29% for Q2 2025, and -111.59% during Q1 2025.